AKR1C1 and acute lymphoblastic leukemia: In this study, we investigated if AKR1C1-3 could contribute to therapy resistance in T-ALL by evaluating the potential impact of AKR1C1-3 expression and inhibition on drug sensitivity in T-ALL cell lines, primary cultures, and PDXs.